1. Introduction {#sec1-ijerph-14-00084}
===============

Coronary artery disease (CAD) is one of the greatest causes of morbidity and mortality throughout the world. It accounts for roughly one-half of all cardiovascular deaths \[[@B1-ijerph-14-00084],[@B2-ijerph-14-00084]\]. Although tobacco use and lipid metabolism disorder are the classical risk factors for CAD, some studies have found that CAD shows strong familial aggregation, and a gene variant is also a key risk marker for CAD patients \[[@B3-ijerph-14-00084],[@B4-ijerph-14-00084]\]. For example, Bai et al. found that the monocyte chemoattractant protein-1 (MCP-1)-2518A\>G polymorphism was associated with susceptibility to CAD, especially in Caucasians \[[@B5-ijerph-14-00084]\]. By contrast, Zhang et al. found that the COX-2--765G\>C (rs20417) polymorphism was protective against CAD \[[@B6-ijerph-14-00084]\]. Meanwhile, a few studies have reported that lipoprotein lipase (LPL) gene polymorphism may be associated with CAD risk.

LPL is a key enzyme for lipid metabolism. It can hydrolyze the triglycerides of chylomicrons and very-low-density lipoprotein (VLDL) to provide free fatty acids for oxidation and utilization in the heart and other tissues, as well as for storage in adipose tissue \[[@B7-ijerph-14-00084],[@B8-ijerph-14-00084]\]. The abnormal expression of LPL is part of some pathophysiological processes, such as diabetes, chylomicronemia, obesity, and atherosclerosis \[[@B9-ijerph-14-00084]\]. The LPL gene is located on chromosome 8p22. Over 100 mutations have been found in this gene \[[@B10-ijerph-14-00084],[@B11-ijerph-14-00084]\]. A few studies have reported that the polymorphisms of HindIII, Ser447X and PvuII were associated with the risk of CAD \[[@B10-ijerph-14-00084],[@B12-ijerph-14-00084],[@B13-ijerph-14-00084],[@B14-ijerph-14-00084]\]. However, these results were also controversial \[[@B14-ijerph-14-00084],[@B15-ijerph-14-00084],[@B16-ijerph-14-00084],[@B17-ijerph-14-00084]\]. Some studies found no association between these gene variants of LPL and the risk of CAD \[[@B14-ijerph-14-00084],[@B15-ijerph-14-00084]\].

In this study, we performed the meta-analysis to explore these inconsistencies between LPL gene variants and the risk of CAD. The results confirmed that the LPL HindIII polymorphism is significantly associated with increased risk of CAD. This polymorphism might serve as a potential biomarker for CAD risk.

2. Materials and Methods {#sec2-ijerph-14-00084}
========================

2.1. Literature Sources and Search Strategies {#sec2dot1-ijerph-14-00084}
---------------------------------------------

The literature included in this study was searched from electronic databases including Embase, China Biological Medicine Database, PubMed, Knowledge Infrastructure, and China National Web of Science. The key words were as follow: "coronary artery disease", "lipoprotein lipase" and "polymorphism". The relative of the references from the retrieved studies were also included. The last search was updated on 15 December 2015, with publication years ranging from 2000 to 2015.

2.2. Inclusion and Exclusion Criteria {#sec2dot2-ijerph-14-00084}
-------------------------------------

The studies were selected based on the following inclusion criteria: the case-control studies discussed the polymorphism of LPL and the risk of CAD; the studies supplied the number of individual genotypes for the LPL polymorphisms in the CAD cases and controls; and the studies conform to the Hardy--Weinberg equilibrium (HWE). In addition, the following exclusion criteria were used: the study did not provide the detailed data that are typically presented in abstracts, meeting reports and reviews; the genotype frequency was not reported; and the studies repeated or overlapped other publications.

2.3. Data Extraction {#sec2dot3-ijerph-14-00084}
--------------------

The information was drawn out according to a standard protocol. Repeated publications were only adopted once and studies violating the inclusion criteria or providing insufficient data were excluded. The extracted data in [Table 1](#ijerph-14-00084-t001){ref-type="table"} comprise the following items: the first author's name, publication date, region of study, ethnicity of the sample population, number of genotypes, total number of cases and controls and HWE. Two authors (Li Xie and You-Mei Li) independently extracted the above information and disagreement was discussed by all authors to obtain consensus.

2.4. Statistical Analyses {#sec2dot4-ijerph-14-00084}
-------------------------

Deviation from the Hardy--Weinberg equilibrium was examined by the Chi-square test. The odds ratio (OR) and the corresponding 95% confidence interval (CI) between the case and control groups was used to assess the strength of the association between the LPL polymorphisms and the risk of CAD. For the HindIII, Ser447X and PvuII polymorphisms, we pooled the OR by comparing the risk allele carrier genotypes versus the wild-type genotype for low frequency of the homozygous variant. The statistical significance of the summary OR was determined by the Z test with the significance set as *p* value less than 0.05. If there was heterogeneity among the individual studies, the random effects model was adopted to calculate the overall OR value \[[@B18-ijerph-14-00084]\]. Otherwise, the fixed effects model was adopted \[[@B19-ijerph-14-00084]\]. To determine the publication bias, the funnel plot was used. The Egger's linear regression test on the natural logarithm scale of the OR was used to assess the funnel plot asymmetry; the significance was set at the *p* \< 0.05 level \[[@B20-ijerph-14-00084],[@B21-ijerph-14-00084]\]. All statistical analyses were performed with RevMan V.5.0 software (Nordic Cochran Centre: Copenhagen, Denmark).

3. Results {#sec3-ijerph-14-00084}
==========

3.1. Study Characteristics {#sec3dot1-ijerph-14-00084}
--------------------------

The databases of Embase, China Biological Medicine Database, PubMed, Knowledge Infrastructure, and China National Web of Science were used to identify literature for inclusion in this study. The following key words were entered: "coronary artery disease", "lipoprotein lipase" and "polymorphism". Originally, 224 potentially relevant studies were identified and screened. Then, these studies were carefully analyzed and 14 case-control studies were selected \[[@B13-ijerph-14-00084],[@B14-ijerph-14-00084],[@B15-ijerph-14-00084],[@B16-ijerph-14-00084],[@B17-ijerph-14-00084],[@B22-ijerph-14-00084],[@B23-ijerph-14-00084],[@B24-ijerph-14-00084],[@B25-ijerph-14-00084],[@B26-ijerph-14-00084],[@B27-ijerph-14-00084],[@B28-ijerph-14-00084],[@B29-ijerph-14-00084],[@B30-ijerph-14-00084]\]. The detailed study selection process is illustrated in [Figure 1](#ijerph-14-00084-f001){ref-type="fig"}. For the HindIII polymorphism and the risk of CAD, seven studies that involved 1853 cases and 1171 controls were available \[[@B13-ijerph-14-00084],[@B14-ijerph-14-00084],[@B15-ijerph-14-00084],[@B22-ijerph-14-00084],[@B25-ijerph-14-00084],[@B28-ijerph-14-00084],[@B30-ijerph-14-00084]\]. For the Ser447X polymorphism, eight studies that included 1519 cases and 824 controls were available \[[@B14-ijerph-14-00084],[@B15-ijerph-14-00084],[@B23-ijerph-14-00084],[@B24-ijerph-14-00084],[@B25-ijerph-14-00084],[@B26-ijerph-14-00084],[@B28-ijerph-14-00084],[@B29-ijerph-14-00084]\]. For the PvuII polymorphism, six studies with 1064 cases and 832 controls were selected \[[@B14-ijerph-14-00084],[@B15-ijerph-14-00084],[@B16-ijerph-14-00084],[@B17-ijerph-14-00084],[@B25-ijerph-14-00084],[@B27-ijerph-14-00084]\]. All of the studies included in the meta-analysis were consistent with HWE in the control populations. The detailed characteristics of the studies included in this meta-analysis are shown in [Table 1](#ijerph-14-00084-t001){ref-type="table"}. The distribution of HindIII, Ser447X and PvuII polymorphism genotype is listed in [Table 2](#ijerph-14-00084-t002){ref-type="table"}.

3.2. Association of the HindIII Polymorphism with CAD {#sec3dot2-ijerph-14-00084}
-----------------------------------------------------

Data from seven studies that included 1853 cases and 1171 controls were pooled together for analysis of the association between the HindIII polymorphism and the risk of CAD. The overall data showed that individuals who carried the HindIII H^+^H^+^ genotype had a significantly increased CAD risk compared with those who carried the HindIII H^+^H^−^ and H^−^H^−^ genotypes in all subjects (OR = 1.28, 95% CI = 1.09--1.49, *p* = 0.002, I^2^ = 43%, [Figure 2](#ijerph-14-00084-f002){ref-type="fig"}). Because the heterogeneity among the studies was not significant (all *p* \> 0.05), the fixed-effects model was conducted. In addition, we found that the H^+^ allele genotype was significantly associated with increased CAD risk when compared with the H^−^ allele genotype (OR = 1.27, 95% CI = 1.03--1.58, *p* = 0.03, I^2^ = 67%, [Figure 3](#ijerph-14-00084-f003){ref-type="fig"}). It was also determined that the heterozygous and recessive genetic models had no association with the risk of CAD.

3.3. Association of the Ser447X Polymorphism with CAD {#sec3dot3-ijerph-14-00084}
-----------------------------------------------------

Eight studies examining CAD were included for the evaluation of the association with the LPL Ser447X polymorphism. As the heterogeneity was not significant (*p* = 0.06), the fixed-effects model was used. It was determined that the individuals who carried the Ser447X XX genotype had a significantly increased CAD risk compared with those who carried the Ser447X other genotypes in all subjects (OR = 2.37, 95% CI = 1.33--4.24, *p* = 0.004, I^2^ = 53%, [Figure 4](#ijerph-14-00084-f004){ref-type="fig"}). In the X allele genetic model, the heterogeneity was significant (*p* \< 0.0001), and the random-effects model was used for analysis. It was found that X allele genetic model had no significant association with CAD risk (OR = 1.04, 95% CI = 0.60--1.80, *p* = 0.90, I^2^ = 87%). In addition, we analyzed other genetic models and found that the heterozygous and dominant genetic models had no association with the risk of CAD.

3.4. Association of the PvuII Polymorphism with CAD {#sec3dot4-ijerph-14-00084}
---------------------------------------------------

Data from six studies that included 1064 cases and 832 controls were pooled together to analyze the association between the PvuII polymorphism and the risk of CAD. For the dominant genetic model, the fixed-effects model was conducted because the heterogeneity was not significant (*p* = 0.45). It was determined that this genetic model had no significant association with the risk of CAD (OR = 0.96, 95% CI = 0.79--1.17, *p* = 0.68, I^2^ = 0%). It was also determined that the allele genetic model and the heterozygous and recessive genetic models had no associations with the risk of CAD.

3.5. Sensitivity Analyses and Publication Bias {#sec3dot5-ijerph-14-00084}
----------------------------------------------

A single study included in the meta-analysis was excluded following sequential omission. The corresponding pooled ORs were not materially altered in any subjects with either the HindIII or PvuII genotypes, suggesting the stability of the meta-analysis (data not shown). To assess the publication bias of the meta-analysis, Begg's funnel plot and Egger's test were performed. The funnel plot shapes were symmetrical for all the polymorphisms of HindIII and PvuII genotypes (data not shown). The statistical results did not suggest any evidence of publication bias among these studies. However, for Ser447X genotype, it was found that when the study by Ahmadi and colleagues was deleted, the sensitivity analysis was unstable and publication bias existed \[[@B22-ijerph-14-00084]\]. Therefore, it was considered that the association between Ser447X polymorphism and CAD risk still requires further research.

4. Discussion {#sec4-ijerph-14-00084}
=============

In this study, we first performed a meta-analysis for the association between LPL polymorphism and CAD risk. It was found that the LPL HindIII polymorphism was positively correlated with CAD risk. In contrast, the LPL PvuII polymorphism had no association with CAD risk. Further research on the association between LPL Ser447X polymorphism and CAD risk is still needed.

The LPL gene spans over 30 kb, comprising 10 exons and nine introns on chromosome 8p22. Its cDNA is translated to a 475 amino acid proteins, including a 27 amino acid signal peptide. Several sequence variations, including BamHI, PvuII, HindIII, BstNI and Ser447X sites, have been identified by restriction fragment length polymorphisms (RFLPs) in the LPL gene \[[@B31-ijerph-14-00084],[@B32-ijerph-14-00084],[@B33-ijerph-14-00084]\]. Among these variations, the HindIII, Ser447X and PvuII polymorphisms were the most common and may be associated with profound alterations in plasma lipids. Recently, some studies have reported that the HindIII, Ser447X and PvuII gene plolymorphisms decreased plasma LPL activity. Furthermore, decreased plasma LPL activity was associated with elevated TG and low HDL-C levels in patient samples, which can contribute to CAD risk \[[@B34-ijerph-14-00084],[@B35-ijerph-14-00084],[@B36-ijerph-14-00084],[@B37-ijerph-14-00084]\]. The HindIII polymorphism is located in intron 8, 495 bp from the splice-donor site, and it can affect RNA splicing \[[@B38-ijerph-14-00084]\]. The H-allele of the HindIII polymorphism could cause either enhanced enzyme activity or more efficient lipid binding \[[@B34-ijerph-14-00084]\]. The Ser447X polymorphism is located in intron 9, where cytosine (C) is replaced by guanine (G), at position 1959. This polymorphism leads to the suppression of the final two amino acids, serine and glycine at position 447 of protein \[[@B35-ijerph-14-00084],[@B36-ijerph-14-00084]\]. The PvuII polymorphism is located on intron 6, 1.57 kb from the SA site. The region containing the PvuII site resembles the splicing site in its homology to the consensus sequence required for 39-splicing and the formation of the lariat structure, suggesting that C497-T change may interfere with the correct splicing of messenger RNA \[[@B17-ijerph-14-00084],[@B37-ijerph-14-00084]\].

The association between the LPL polymorphism and CAD has been researched for thirty years. However, the results to date have been inconsistent. Currently, there are no large scale case control studies for LPL polymorphism and CAD risk. Thus, we performed a meta-analysis to study the association between LPL polymorphism and CAD risk. To analyze the association between the HindIII polymorphism and CAD risk, we reviewed seven studies including 1853 cases and 1171 controls that were conducted from 2000 to 2015. As shown in [Figure 2](#ijerph-14-00084-f002){ref-type="fig"} and [Figure 3](#ijerph-14-00084-f003){ref-type="fig"}, the analysis revealed that the HindIII H^+^H^+^ genotype and the H^+^ allele genotype were significantly associated with the risk of CAD. These results were consistent with previous reports that HindIII is the most common polymorphism of LPL associated with CAD risk. However, for the Ser447X polymorphism, the association with CAD was only found in the XX genotype; the other genotype had no significant association. The difference in the XX genotype may have been caused by publication bias because two studies reported no events in the XX genotype \[[@B15-ijerph-14-00084],[@B25-ijerph-14-00084]\]. More studies are needed to confirm this result. For the PvuII polymorphism, no significant association to CAD risk was detected.

However, there are some limitations in this study. First, based on our inclusion and exclusion criteria, the available studies that could be included in this meta-analysis were moderate. Thus, the results may be influenced by factors such as random error. Second, the results were based on individual unadjusted effect estimates, whereas a more precise evaluation would be adjusted by other potential risk factors, including age, sex, drinking status, cigarette consumption, etc. Third, the lack of individual-level data prevented further analyses to identify interactions between the genetic variations and the metabolic traits.

5. Conclusions {#sec5-ijerph-14-00084}
==============

In conclusion, we found that the LPL polymorphisms HindIII H^+^H^+^ genotype and H^+^ allele genotype were significantly associated with the risk of CAD. The Ser447X XX genotype was also significantly associated with the risk of CAD. However, more studies are needed to confirm these findings. In contrast, the PvuII polymorphism had no association with the risk of CAD. We have concluded that LPL HindIII polymorphism might serve as a potential biomarker for CAD risk.

Li Xie and You-Mei Li conceived this work and interpreted the data. You-Mei Li and Li Xie wrote the main manuscript and prepared all figures and tables. Both authors reviewed the manuscript.

The authors declare no competing financial interests.
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ijerph-14-00084-t001_Table 1

###### 

Characteristics of studies included in meta-analysis.

  Study                                  Years   Ethnicity       No. of Case/Control   Matching Criteria   Control Source   Genotyping   HWE
  -------------------------------------- ------- --------------- --------------------- ------------------- ---------------- ------------ -----
  **HindⅢ Polymorphism**                                                                                                                 
  Abu-Amero \[[@B14-ijerph-14-00084]\]   2003    Saudi Arabian   352/410               Sex, Age            HB               PCR          Yes
  Ahmadi \[[@B22-ijerph-14-00084]\]      2015    Iranian         108/89                Sex, Age            HB               PCR          Yes
  Al-Jafari \[[@B15-ijerph-14-00084]\]   2012    Saudi Arabian   120/65                Sex, Age            HB               PCR          Yes
  Daoud \[[@B25-ijerph-14-00084]\]       2013    Saudi Arabian   226/103               Sex, Age            HB               PCR          Yes
  Pasalic \[[@B28-ijerph-14-00084]\]     2006    Croatian        132/98                Sex, Age            HB               PCR          Yes
  Tanguturi \[[@B13-ijerph-14-00084]\]   2013    Indian          202/210               Sex, Age            HB               PCR          Yes
  Whiting \[[@B30-ijerph-14-00084]\]     2004    American        713/196               Sex, Age            HB               PCR          Yes
  **PvuII Polymorphism**                                                                                                                 
  Abu-Amero \[[@B14-ijerph-14-00084]\]   2003    Saudi Arabian   431/511               Sex, Age            HB               PCR          Yes
  Al-Jafari \[[@B15-ijerph-14-00084]\]   2012    Saudi Arabian   120/65                Sex, Age            HB               PCR          Yes
  Daoud \[[@B25-ijerph-14-00084]\]       2013    Saudi Arabian   226/103               Sex, Age            HB               PCR          Yes
  Duman \[[@B17-ijerph-14-00084]\]       2004    Turkish         78/49                 Sex, Age            HB               PCR          Yes
  Georgiev \[[@B16-ijerph-14-00084]\]    2008    Macedonian      109/32                Sex, Age            HB               PCR          Yes
  Isbir \[[@B27-ijerph-14-00084]\]       2003    Turkish         100/72                Sex, Age            HB               PCR          Yes
  **Ser447X Polymorphism**                                                                                                               
  Ahmadi \[[@B22-ijerph-14-00084]\]      2015    Iranian         115/89                Sex, Age            HB               PCR          Yes
  Al-Jafari \[[@B15-ijerph-14-00084]\]   2012    Saudi Arabian   120/65                Sex, Age            HB               PCR          Yes
  Almeida \[[@B23-ijerph-14-00084]\]     2006    Brazil          313/150               Sex, Age            HB               PCR          Yes
  Aydogan \[[@B24-ijerph-14-00084]\]     2009    Turkey          41/23                 Sex, Age            HB               PCR          Yes
  Daoud \[[@B25-ijerph-14-00084]\]       2013    Saudi Arabian   226/103               Sex, Age            HB               PCR          Yes
  Ferencak \[[@B26-ijerph-14-00084]\]    2003    Croatian        479/200               Sex, Age            HB               PCR          Yes
  Pasalic \[[@B28-ijerph-14-00084]\]     2006    Croatian        132/98                Sex, Age            HB               PCR          Yes
  Sawano \[[@B29-ijerph-14-00084]\]      2001    Japanese        93/96                 Sex, Age            HB               PCR          Yes

HB: hospital based, HWE: Hardy--Weinberg equilibrium.

ijerph-14-00084-t002_Table 2

###### 

Genotypes and allele frequencies of Lipoprotein Lipase (LPL) genes in patients and controls.

  Author                                 Year           Case           Control        Sample Size   HWE (P)                                                                                       
  -------------------------------------- -------------- -------------- -------------- ------------- ---------- -------------- -------------- -------------- ---------- ---------- ----- --------- -----
  **HindⅢ Polymorphism**                 **H^+^H^+^**   **H^+^H^−^**   **H^−^H^−^**   **H^+^**      **H^−^**   **H^+^H^+^**   **H^+^H^−^**   **H^−^H^−^**   **H^+^**   **H^−^**                   
  Abu-Amero \[[@B14-ijerph-14-00084]\]   2003           189            138            25            516        188            206            173            31         585        235   352/410   Yes
  Pasalic \[[@B28-ijerph-14-00084]\]     2006           78             46             8             202        62             47             45             6          139        57    132/98    Yes
  Whiting \[[@B30-ijerph-14-00084]\]     2005           385            269            59            1039       387            103            77             16         283        109   713/196   Yes
  Daoud \[[@B25-ijerph-14-00084]\]       2013           102            81             43            285        167            42             35             26         119        87    226/103   Yes
  Al-Jafari \[[@B15-ijerph-14-00084]\]   2012           61             53             6             175        65             29             23             13         81         49    120/65    Yes
  Tanguturi \[[@B13-ijerph-14-00084]\]   2013           98             72             32            268        136            70             68             72         208        212   202/210   Yes
  Ahmadi \[[@B22-ijerph-14-00084]\]      2015           61             41             6             163        53             53             33             3          139        39    108/89    Yes
  **Ser447X Polymorphism**               **SS**         **SX**         **XX**         **S**         **X**      **SS**         **SX**         **XX**         **S**      **X**                      
  Ahmadi \[[@B22-ijerph-14-00084]\]      2015           58             23             34            139        91             75             7              7          157        21    115/89    Yes
  Al-Jafari \[[@B15-ijerph-14-00084]\]   2012           100            20             0             220        20             57             8              0          122        8     120/65    Yes
  Almeida \[[@B23-ijerph-14-00084]\]     2007           257            47             9             561        65             115            34             1          264        36    313/150   Yes
  Aydogan \[[@B24-ijerph-14-00084]\]     2009           27             10             4             64         18             17             2              4          36         10    41/23     Yes
  Daoud \[[@B25-ijerph-14-00084]\]       2013           185            41             0             411        41             92             11             0          195        11    226/103   Yes
  Ferencak \[[@B26-ijerph-14-00084]\]    2003           378            97             4             853        105            167            32             1          366        34    479/200   Yes
  Pasalic \[[@B28-ijerph-14-00084]\]     2006           113            19             0             245        19             69             28             1          166        30    132/98    Yes
  Sawano \[[@B29-ijerph-14-00084]\]      2001           82             10             1             174        12             71             23             2          145        27    93/96     Yes
  **PvuII Polymorphism**                 **P^+^P^+^**   **P^+^P^−^**   **P^−^P^−^**   **P^+^**      **P^−^**   **P^+^P^+^**   **P^+^P^−^**   **P^−^P^−^**   **P^+^**   **P^−^**                   
  Abu-Amero \[[@B14-ijerph-14-00084]\]   2003           138            225            68            501        361            182            248            81         612        410   431/511   Yes
  Al-Jafari \[[@B15-ijerph-14-00084]\]   2012           50             52             18            152        88             25             28             12         78         52    120/65    Yes
  Daoud \[[@B25-ijerph-14-00084]\]       2013           89             102            35            280        172            46             44             13         136        70    226/103   Yes
  Duman \[[@B17-ijerph-14-00084]\]       2004           25             39             14            89         67             14             16             19         44         54    78/49     Yes
  Georgiev \[[@B16-ijerph-14-00084]\]    2008           25             58             26            158        110            5              20             7          30         34    109/32    Yes
  Isbir \[[@B27-ijerph-14-00084]\]       2003           37             49             14            123        77             20             40             12         80         64    100/72    Yes

[^1]: These authors contributed equally to this study.
